JP2022531231A5 - - Google Patents
Info
- Publication number
- JP2022531231A5 JP2022531231A5 JP2021564498A JP2021564498A JP2022531231A5 JP 2022531231 A5 JP2022531231 A5 JP 2022531231A5 JP 2021564498 A JP2021564498 A JP 2021564498A JP 2021564498 A JP2021564498 A JP 2021564498A JP 2022531231 A5 JP2022531231 A5 JP 2022531231A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cells
- seq
- optionally
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841748P | 2019-05-01 | 2019-05-01 | |
| US201962841753P | 2019-05-01 | 2019-05-01 | |
| US62/841,753 | 2019-05-01 | ||
| US62/841,748 | 2019-05-01 | ||
| PCT/US2020/030818 WO2020223537A1 (en) | 2019-05-01 | 2020-04-30 | Compositions and methods for the treatment of cancer using a cdb engineered t cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531231A JP2022531231A (ja) | 2022-07-06 |
| JP2022531231A5 true JP2022531231A5 (enExample) | 2023-05-12 |
| JP7717619B2 JP7717619B2 (ja) | 2025-08-04 |
Family
ID=73029470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564498A Active JP7717619B2 (ja) | 2019-05-01 | 2020-04-30 | Ｃｄ８改変ｔ細胞療法を使用するがんの治療のための組成物及び方法 |
| JP2021564500A Pending JP2022530653A (ja) | 2019-05-01 | 2020-04-30 | Ｔｅｔ２改変ｔ細胞療法を使用するがんの治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564500A Pending JP2022530653A (ja) | 2019-05-01 | 2020-04-30 | Ｔｅｔ２改変ｔ細胞療法を使用するがんの治療のための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20210085720A1 (enExample) |
| EP (2) | EP3962938A4 (enExample) |
| JP (2) | JP7717619B2 (enExample) |
| KR (2) | KR20220005050A (enExample) |
| CN (1) | CN113748127B (enExample) |
| AU (2) | AU2020264484A1 (enExample) |
| CA (2) | CA3136740A1 (enExample) |
| IL (2) | IL287643A (enExample) |
| MX (2) | MX2021013218A (enExample) |
| SG (2) | SG11202111865UA (enExample) |
| WO (3) | WO2020223537A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166226B (zh) * | 2018-09-28 | 2025-06-27 | 纪念斯隆-凯特琳癌症中心 | 表达显性负性fas的免疫应答细胞及其用途 |
| KR20220051401A (ko) * | 2019-09-06 | 2022-04-26 | 크리스퍼 테라퓨틱스 아게 | 배양 중 개선된 지속성을 갖는 유전적으로 조작된 t 세포 |
| WO2021216993A1 (en) * | 2020-04-24 | 2021-10-28 | Pact Pharma, Inc. | Methods of determining gene editing efficiencies in cells |
| WO2022109277A1 (en) * | 2020-11-20 | 2022-05-27 | Pact Pharma, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY |
| WO2022132836A2 (en) * | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| WO2022140361A1 (en) * | 2020-12-22 | 2022-06-30 | Ludwig Institute For Cancer Research Ltd | Genetically engineered lymphocytes for adoptive cell therapy |
| WO2022177970A1 (en) * | 2021-02-18 | 2022-08-25 | University Of Florida Research Foundation, Incorporated | Enhancing metabolic fitness of t cells to treat cancer |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| EP4298230A1 (en) | 2021-02-25 | 2024-01-03 | Lyell Immunopharma, Inc. | Codon-optimized nucleotide sequences encoding an ap-1 transcription factor |
| WO2022242644A1 (zh) * | 2021-05-18 | 2022-11-24 | 赛斯尔擎生物技术（上海）有限公司 | 修饰细胞的方法 |
| EP4352508A1 (en) * | 2021-06-11 | 2024-04-17 | Adoc Ssf, Llc | Method of assessing cell products |
| EP4405464A4 (en) * | 2021-09-21 | 2025-12-03 | Univ Chicago | METHODS AND COMPOSITION USING PATIENT-DERIVED AUTOLOGOUS NEOANTIGENS FOR CANCER TREATMENT |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| IL312201A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing c-jun |
| CN114373511B (zh) * | 2022-03-15 | 2022-08-30 | 南方医科大学南方医院 | 基于5hmC分子标志物检测的肠癌模型及肠癌模型构建方法 |
| WO2023212507A1 (en) * | 2022-04-26 | 2023-11-02 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
| CN120112636A (zh) * | 2022-09-19 | 2025-06-06 | 埃门多生物公司 | Faslg双等位基因敲除 |
| JP2025529540A (ja) * | 2022-09-19 | 2025-09-04 | エメンドバイオ・インコーポレイテッド | Ｔｅｔ２の両アレルノックアウト |
| US20260091113A1 (en) * | 2022-09-19 | 2026-04-02 | Emendobio Inc. | Biallelic Knockout of CTLA4 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| CN121752591A (zh) | 2023-07-03 | 2026-03-27 | 新免疫技术有限公司 | 异源二聚体Fc分子及其用途 |
| AU2024316049A1 (en) * | 2023-07-31 | 2026-02-12 | T-Knife Gmbh | An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease |
| AU2024332117A1 (en) * | 2023-08-25 | 2026-02-12 | T-Knife Gmbh | Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US20020127594A1 (en) * | 2000-06-22 | 2002-09-12 | Gearing David P. | Don-1 gene and polypeptides and uses therefor |
| US6355412B1 (en) * | 1999-07-09 | 2002-03-12 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
| US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| US8119772B2 (en) * | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| WO2013033626A2 (en) * | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| US10316289B2 (en) * | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| MX373687B (es) * | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| US10975137B2 (en) * | 2014-11-06 | 2021-04-13 | University Of Maryland, Baltimore | CD8a and t cell receptor variants and methods of using same in modulating immune cell responses |
| EP4248744A3 (en) * | 2015-04-06 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
| CA2996887A1 (en) * | 2015-09-11 | 2017-03-16 | Agenus Inc. | Engineered host cells and methods of use thereof |
| AU2016323985B2 (en) * | 2015-09-17 | 2022-12-15 | Novartis Ag | CAR T cell therapies with enhanced efficacy |
| BR112018012235A2 (pt) * | 2015-12-18 | 2018-12-04 | Sangamo Therapeutics Inc | rompimento alvejado do receptor de células de mhc |
| EP3440101B1 (en) * | 2016-04-04 | 2021-10-06 | Indi Molecular, Inc. | Cd8-specific capture agents, compositions, and methods of using and making |
| CN109996868A (zh) * | 2016-09-23 | 2019-07-09 | 弗雷德哈钦森癌症研究中心 | 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途 |
| KR20240024328A (ko) * | 2016-11-22 | 2024-02-23 | 알로플렉스 바이오테라퓨틱스 | 동종이형 종양 세포 백신 |
| JP7037577B2 (ja) * | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| CN110831619A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 具有增强功效的生物标志和car t细胞疗法 |
| WO2018175636A2 (en) * | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| US11512287B2 (en) * | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| WO2019004831A1 (en) * | 2017-06-30 | 2019-01-03 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
| AU2018329741B2 (en) * | 2017-09-08 | 2025-02-20 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression |
| SG11202004026QA (en) * | 2017-10-30 | 2020-05-28 | Pact Pharma Inc | Primary cell gene editing |
| WO2019136335A1 (en) * | 2018-01-05 | 2019-07-11 | Gencyte Therapeutics, Inc. | Precision molecular adaptor system for car-t immunotherapy |
| IL277722B2 (en) | 2018-04-02 | 2025-12-01 | Pact Pharma Inc | Peptide-mhc compacts |
| WO2020049496A1 (en) * | 2018-09-05 | 2020-03-12 | Glaxosmithkline Intellectual Property Development Limited | T cell modification |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| IL285534B2 (en) | 2019-02-12 | 2025-04-01 | Pact Pharma Inc | Preparations and methods for identifying antigen-specific T cells |
| WO2020243134A1 (en) * | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
-
2020
- 2020-04-30 SG SG11202111865UA patent/SG11202111865UA/en unknown
- 2020-04-30 KR KR1020217038747A patent/KR20220005050A/ko not_active Withdrawn
- 2020-04-30 KR KR1020217038746A patent/KR20220004703A/ko active Pending
- 2020-04-30 SG SG11202111532SA patent/SG11202111532SA/en unknown
- 2020-04-30 JP JP2021564498A patent/JP7717619B2/ja active Active
- 2020-04-30 CA CA3136740A patent/CA3136740A1/en active Pending
- 2020-04-30 CN CN202080032593.3A patent/CN113748127B/zh active Active
- 2020-04-30 WO PCT/US2020/030818 patent/WO2020223537A1/en not_active Ceased
- 2020-04-30 CA CA3151385A patent/CA3151385A1/en active Pending
- 2020-04-30 MX MX2021013218A patent/MX2021013218A/es unknown
- 2020-04-30 WO PCT/US2020/030704 patent/WO2020223478A1/en not_active Ceased
- 2020-04-30 AU AU2020264484A patent/AU2020264484A1/en active Pending
- 2020-04-30 MX MX2021013225A patent/MX2021013225A/es unknown
- 2020-04-30 AU AU2020266579A patent/AU2020266579A1/en not_active Abandoned
- 2020-04-30 EP EP20798669.6A patent/EP3962938A4/en active Pending
- 2020-04-30 JP JP2021564500A patent/JP2022530653A/ja active Pending
- 2020-04-30 EP EP20798347.9A patent/EP3953379A4/en active Pending
- 2020-05-01 WO PCT/US2020/031007 patent/WO2020223625A1/en not_active Ceased
- 2020-11-16 US US17/099,140 patent/US20210085720A1/en not_active Abandoned
- 2020-11-20 US US17/100,223 patent/US11304978B2/en active Active
-
2021
- 2021-10-27 IL IL287643A patent/IL287643A/en unknown
- 2021-10-27 IL IL287639A patent/IL287639A/en unknown
-
2022
- 2022-03-10 US US17/691,565 patent/US12247061B2/en active Active
-
2025
- 2025-02-04 US US19/044,972 patent/US20260001931A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531231A5 (enExample) | ||
| JP6612963B2 (ja) | 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法 | |
| US20250101080A1 (en) | Chimeric antigen receptors and uses thereof | |
| KR101890638B1 (ko) | Car 발현 벡터 및 car 발현 t 세포 | |
| JP6359520B2 (ja) | Ｂ細胞成熟抗原を標的指向するキメラ抗原受容体 | |
| JP2025090690A (ja) | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 | |
| JP2024138280A5 (enExample) | ||
| JP2021530999A5 (enExample) | ||
| US20110280894A1 (en) | Her2/neu specific t cell receptors | |
| US20250250319A1 (en) | Chimeric transmembrane polypeptides comprising a tgf beta receptor extracellular domain, a transmembrane domain and an interleukin receptor 2 intracellular signalling domain and its use in therapy | |
| JP2019506154A (ja) | 組換えｔ細胞受容体を含む組成物及びライブラリー並びに組換えｔ細胞受容体を使用する方法 | |
| EP4613762A1 (en) | Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8 | |
| JP2021525534A5 (enExample) | ||
| JP2025508050A (ja) | Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞 | |
| EP3841113A1 (en) | Immunotherapy targeting kras or her2 antigens | |
| CN113286815B (zh) | 间皮素特异性t细胞受体及其在免疫治疗中的应用 | |
| EP4061385A1 (en) | A method for redesign and expansion of nk92 cells for use in immunotherapy | |
| JP7518915B2 (ja) | Ｃｄ３融合タンパク質およびその使用 | |
| EP4328239A1 (en) | Immunotherapeutics based on magea1-derived epitopes | |
| WO2018033544A1 (en) | Method for the generation of t cell hybridoma for cloning and analysis of receptors using engineered measles virus fusogenic glycoproteins | |
| TW202548008A (zh) | 治療腫瘤之組合物和方法 | |
| WO2025193663A2 (en) | Compositions and methods for treating neoplasia | |
| HK40060048A (en) | T cell receptors specific for mesothelin and their use in immunotherapy | |
| CN117813384A (zh) | 嵌合抗原受体、表达前述受体的细胞、包含前述细胞的医药组合物、前述细胞的制造方法、及包含编码前述嵌合抗原受体的碱基序列的多核苷酸或载体 | |
| HK40109914A (zh) | 抗egfrviii抗体、多肽、表达前述多肽的细胞、包含前述细胞的医药组合物、前述细胞的制造方法、及包含编码前述多肽的碱基序列的多核苷酸或载体 |